Comparative Pharmacology
Head-to-head clinical analysis: AVANDAMET versus PIOGLITAZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVANDAMET versus PIOGLITAZONE.
AVANDAMET vs PIOGLITAZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVANDAMET combines rosiglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPARγ), and metformin, a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Selective agonist at peroxisome proliferator-activated receptor-gamma (PPAR-γ), modulating transcription of genes involved in glucose and lipid metabolism, increasing insulin sensitivity in adipose tissue, muscle, and liver.
Oral, initial dose of rosiglitazone 4 mg/metformin 500 mg twice daily or rosiglitazone 2 mg/metformin 500 mg twice daily; maximum recommended dose rosiglitazone 8 mg/metformin 2000 mg per day.
15-30 mg orally once daily; maximum dose 45 mg/day.
None Documented
None Documented
Clinical Note
moderatePioglitazone + Gatifloxacin
"Pioglitazone may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderatePioglitazone + Rosoxacin
"Pioglitazone may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderatePioglitazone + Levofloxacin
"Pioglitazone may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderatePioglitazone + Trovafloxacin
"Pioglitazone may increase the hypoglycemic activities of Trovafloxacin."
Rosiglitazone: 3-4 hours (terminal); metformin: 6.2 hours (terminal). No accumulation with normal renal function.
Terminal elimination half-life is 3-7 hours in healthy adults, but extends to 16-24 hours in patients with hepatic impairment due to reduced clearance. Steady-state is achieved after 4-6 days of dosing.
Renal (90-95% as unchanged drug for rosiglitazone; metformin is 90% renally eliminated unchanged). Biliary/fecal: minor (<5% for both).
Primarily hepatic metabolism via CYP2C8 and CYP3A4; approximately 15-30% excreted in urine as metabolites, with the remainder in feces (~70%) via biliary elimination. Renal excretion of unchanged drug is negligible (<1%).
Category C
Category A/B
Thiazolidinedione and Biguanide Combination
Thiazolidinedione